Products: Lead drug CZC
Our lead drug candidate, CZC, is an improved form of the drug 9-NitroCamptothecin (9NC). As has been reviewed in the About Us: Background page, even with very low blood levels of active drug (< 5%), clinical studies showed significant activity and improved survival outcomes in patients with advanced pancreatic cancer. CZC has been synthesized to significantly improve blood levels, yet retain this high degree of anti-cancer activity. In vitro studies show that when CZC is incubated with Human Serum Albumin (HSA), blood levels of active drug are increased more than tenfold compared to 9NC. This increase in drug availability should translate into an even higher degree of efficacy. Clinical trails are planned to start in 2016.